Treatment of Pulmonary Aspergillosis
Voriconazole is the first-line treatment for invasive pulmonary aspergillosis, dosed at 6 mg/kg IV every 12 hours for 2 doses, then 4 mg/kg IV every 12 hours (or 200 mg orally every 12 hours once stable). 1
Invasive Pulmonary Aspergillosis (IPA)
Primary Treatment Options
The treatment approach depends on the specific form of pulmonary aspergillosis, but for invasive disease:
First-line therapy:
- Voriconazole is the gold standard based on a landmark randomized trial showing superior survival (71% at 12 weeks) compared to amphotericin B deoxycholate (58% survival), with a 21% absolute improvement in successful outcomes (53% vs 32%) 1
- Isavuconazole is an equally acceptable first-line alternative with comparable efficacy and potentially better tolerability 2, 3
Alternative first-line options:
- Liposomal amphotericin B (L-AmB) at 3-5 mg/kg/day IV is appropriate when triazoles cannot be used 1
- A randomized trial showed 3 mg/kg/day and 10 mg/kg/day L-AmB had similar efficacy but the higher dose caused more toxicity 1
Salvage Therapy
For patients failing or intolerant of primary therapy 1:
- Posaconazole (200 mg QID initially, then 400 mg BID after stabilization)
- Echinocandins (caspofungin 70 mg day 1, then 50 mg/day; or micafungin 100-150 mg/day)
- Itraconazole (dosing depends on formulation)
- Switch to a different drug class is recommended for breakthrough IPA on azole prophylaxis 1, 4
Combination Therapy
Routine combination therapy is NOT recommended for primary treatment based on lack of definitive clinical data showing mortality benefit 1, 2. However, the 2025 ATS guideline provides a conditional recommendation that either combination therapy (mold-active triazole plus echinocandin) OR monotherapy may be used, acknowledging the evidence is low-quality 2. In salvage situations, adding an agent from a different class may be considered 1.
Duration of Treatment
- Minimum 6-12 weeks for most patients 1
- Continue throughout the period of immunosuppression and until radiographic lesions resolve 1
- Oral voriconazole facilitates long-term therapy in stable patients 1
Critical Management Points
Early initiation is essential: Start antifungal therapy immediately when IPA is strongly suspected while diagnostic workup proceeds—delays worsen mortality 1, 4
Monitor for progression: Pulmonary infiltrates may increase during the first 7-10 days of therapy, especially with neutrophil recovery—this does not necessarily indicate treatment failure 1
Reversal of immunosuppression is crucial for favorable outcomes when feasible 1
Chronic Cavitary Pulmonary Aspergillosis (CCPA)
- Itraconazole or voriconazole are preferred due to excellent oral bioavailability and cavity penetration 1
- Requires protracted therapy measured in months (minimum 6 months, often 9+ months for CCPA) 1, 4
- Patients without symptoms or progressive disease may be observed without treatment 4
Aspergilloma
- No therapy or surgical resection are the primary approaches 1
- Medical therapy role is uncertain due to poor drug penetration into preexisting cavities (except itraconazole shows excellent penetration) 1
Allergic Bronchopulmonary Aspergillosis (ABPA)
- Corticosteroids are the cornerstone of therapy 1
- Itraconazole has a demonstrable corticosteroid-sparing effect and is the preferred antifungal 1
- Alternative azoles: voriconazole 200 mg PO every 12 hours or posaconazole 400 mg PO BID 1
Important Caveats
Drug interactions: Voriconazole has significant CYP450 interactions, particularly problematic with anticonvulsants in CNS aspergillosis 1
Therapeutic drug monitoring: Consider for voriconazole due to pharmacokinetic variability 1
Avoid deoxycholate amphotericin B as primary therapy—it has inferior outcomes and significant nephrotoxicity risk compared to voriconazole 1
Critically ill ICU patients: In those with COPD, liver cirrhosis, or viral pneumonia (influenza, COVID-19) who fail to improve on antibiotics, maintain high suspicion for IPA and initiate early diagnostic bronchoscopy with galactomannan testing 3